Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL271367 | 0.91 | PLA2G2C (0.33) | — | |
| SCHEMBL270980 | 0.90 | — | — | |
| SCHEMBL271828 | 0.89 | MAPT (0.36) | — | |
| SCHEMBL277536 | 0.87 | MAPT (0.39) | — | |
| SCHEMBL6763012 | 0.85 | — | — | |
| SCHEMBL271666 | 0.84 | PLA2G2C (0.35) | — | |
| SCHEMBL270648 | 0.82 | MAPT (0.39) | — | |
| SCHEMBL270098 | 0.80 | MAPT (0.38) | — | |
| SCHEMBL11111748 | 0.80 | MAPT (0.42) | — | |
| SCHEMBL3026850 | 0.79 | DNM1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5830864-A | RIBONUCLEOTIDE REDUCTASE INHIBITOR | BOEHRINGER INGELHEIM (CANADA), LTD. (CA) | 1998-11-03 | — | — | US | claimed |
| EP-0560267-B1 | Isosteric antiherpes peptide derivatives | BOEHRINGER INGELHEIM CA LTD (CA) | 1998-08-19 | — | — | EP | claimed |
| EP-0560274-B1 | Antiherpes peptide derivatives having a ureido N-terminus | BOEHRINGER INGELHEIM CA LTD (CA) | 1998-06-24 | — | — | EP | claimed |
| EP-0767671-A1 | METHOD OF COMBATING ACYCLOVIR-RESISTANT HERPES SIMPLEX VIRAL INFECTIONS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1997-04-16 | — | — | EP | claimed |
| US-5574015-A | Isosteric antiherpes peptide derivatives | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1996-11-12 | — | — | US | claimed |
| WO-1994025046-A1 | METHOD OF COMBATING ACYCLOVIR-RESISTANT HERPES SIMPLEX VIRAL INFECTIONS | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-11-10 | — | — | WO | claimed |
| WO-1993018056-A1 | ISOSTERIC ANTIHERPES PEPTIDE DERIVATIVES | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-16 | — | — | WO | claimed |
| EP-0560274-A1 | Antiherpes peptide derivatives having a ureido N-terminus | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-15 | — | — | EP | claimed |
| EP-0560267-A1 | Isosteric antiherpes peptide derivatives | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-15 | — | — | EP | claimed |
| EP-2308838-B1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLYL COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2016-02-17 | — | — | EP | disclosed |
| US-9150563-B2 | Nitrogen-containing aromatic heterocyclyl compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20140187592-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLYL COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-07-03 | — | — | US | disclosed |
| US-8648103-B2 | Nitrogen-containing aromatic heterocyclyl compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-02-11 | — | — | US | disclosed |
| US-8236789-B2 | 1-adamantyl azetidin-2-one derivatives and drugs containing same | KOWA COMPANY, LTD. (JP) | 2012-08-07 | — | — | US | disclosed |
| US-5420126-A | Potassium channel activators | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1995-05-30 | — | — | US | disclosed |
| WO-1994025046-A1 | METHOD OF COMBATING ACYCLOVIR-RESISTANT HERPES SIMPLEX VIRAL INFECTIONS | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-11-10 | — | — | WO | disclosed |
| WO-1993018056-A1 | ISOSTERIC ANTIHERPES PEPTIDE DERIVATIVES | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-16 | — | — | WO | disclosed |
| EP-0560274-A1 | Antiherpes peptide derivatives having a ureido N-terminus | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-15 | — | — | EP | disclosed |
| EP-0560267-A1 | Isosteric antiherpes peptide derivatives | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-15 | — | — | EP | disclosed |
| EP-0432893-A2 | Benzoxazine derivatives, their preparation and pharmaceutical compositions containing them | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1991-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187592-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLYL COMPOUND | NPR1, NPR3, NPC1 | TAS1R3 2381/4885TAS1R1 2049/4885HDAC7 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.